NHS ester-PEG4-Val-Cit-PAB-MMAE

NHS ester-PEG4-Val-Cit-PAB-MMAE

NHS ester-PEG4-Val-Cit-PAB-MMAE can be used antibody drug conjugation as a precursor. It contains a PEG4 spacer, a protease-sensitive Val-Cit dipeptide, a PAB linker and an MMAE payload. Please contact us for GMP-grade inquiries.

Molecular structure of the compound BP-25503
    • Unit
    • Price
    • Qty
    • 5 MG
    • $940.00
    • 10 MG
    • $1500.00
    • 25 MG
    • $2800.00

Usually ships within 24 hours.

Would you like to inquire about custom quantity?
Inquire

Product Citations

  1. Doherty, C. D.; Jain, S.; Ott, L. L.; Bakken, K. K.; Wilbanks, B. A.; Burgenske, D. M.; Pearson, K. S.; Griffith, J. I.; Tian, Z.; Meridew, J. A.; Yerneni, S. S.; Elmquist, W. F.; Sarkaria, J. N.; Maher, L. J. In Vivo Selection of Anti-Glioblastoma DNA Aptamer-Drug Conjugates in an Orthotopic Patient-Derived Xenograft Model. 2026.
    https://doi.org/10.64898/2026.02.16.706148
  2. Huang, C. H., Chang, E., Zheng, L., Raj, J. G. J., Wu, W., Pisani, L. J., & Daldrup-Link, H. E. (2023). Tumor protease-activated theranostic nanoparticles for MRI-guided glioblastoma therapy. Theranostics, 13(6), 1745–1758. https://doi.org/10.7150/thno.79342
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091873/
  3. Kumru, K., Yao, Z., Holmes, B. B., Zhao, F., Zhang, Y., Ferrara, E., ... & Wells, J. A. (2025). A cytokine receptor-targeting chimera (kineTAC) toolbox for expanding extracellular targeted protein degradation. bioRxiv, 2025-09.
    https://www.biorxiv.org/content/10.1101/2025.09.02.673832v1.full
  4. Kumru, K.; Yao, Z.; Holmes, B. B.; Zhao, F.; Zhang, Y.; Ferrara, E.; Peters-Clarke, T. M.; Leung, K. K.; Wells, J. A. A Cytokine Receptor–Targeting Chimera Toolbox for Expanding Extracellular Targeted Protein Degradation. Proceedings of the National Academy of Sciences 2026, 123
    https://doi.org/10.1073/pnas.2524129123
  5. Njotu, F. N., Garcia, M. D., Nwangele, E., Babeker, H., Ketchemen, J. P., Price, E. W., ... & Fonge, H. Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple negative breast cancer models. Available at SSRN 5994000.
    https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5994000
  6. Yen-Pang HSU, Sampat L. INGALE. Bisecting-glycan bridged conjugation for producing glycoprotein conjugates. (EP4615513A1)
    https://patents.google.com/patent/EP4615513A1/en?q=(BROADPHARM)&oq=BROADPHARM&sort=new&page=17
  7. Zhao, F., Wu, Y., Schaefer, K., Zhang, Y., Miao, K., Yao, Z., ... & Wells, J. A. (2025). Hijacking Extracellular Targeted Protein Degrader–Drug Conjugates for Enhanced Drug Delivery. Journal of the American Chemical Society, 147(43), 39912-39925.
    https://pubs.acs.org/doi/full/10.1021/jacs.5c15047
  8. Zhao, F., Wu, Y., Schaefer, K., Zhang, Y., Miao, K., Yao, Z., ... & Wells, J. A. (2025). Low-density lipoprotein receptor-targeting chimeras for membrane protein degradation and enhanced drug delivery. bioRxiv, 2025-06.
    https://www.biorxiv.org/content/10.1101/2025.06.06.658366v1.full